Announcement PDF ASX Announcement 18 August 2025 FY25 Full Year Results and Investor Webcast Notification Cogstate (ASX.CGS) advises that it will release its full year results for the Financial Year ended 30 June 2025 (FY25) on Friday 22 August 2025. Investors are invited to join a live webcast and Q&A hosted by Brad O’Connor, CEO, Darren Watson, CFO and Rachel Colite Executive Vice President, Clinical Trials on Friday 22 August 2025 at 9:00am Australian Eastern Standard Time. Please register at: https://investors.cogstate.com/webinars/7PldLP-cogstate-full-year-fy25-results Additionally, a video recording of the presentation will be available within 24 hours following the presentation at the Cogstate Investor Centre homepage: https://investors.cogstate.com. This announcement was authorised for release by Cogstate CEO, Brad O’Connor. Important Upcoming Dates To stay up to date, sign up to the Cogstate Investor Hub: https://investors.cogstate.com 1. Thursday 16 October 2025 at 11am AEST Annual General Meeting of Shareholders Location: Melbourne Australia and online 2. Friday 7th November 2025 from 9am-2pm AEDT Shareholder Day (in-person): Location: Melbourne Australia. Register here For further information contact: investor@cogstate.com About Cogstate Cogstate Ltd (ASX: CGS) is a neuroscience technology company optimising brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable and highly sensitive computerised cognitive tests across a growing list of domains and support partners in the delivery of electronic clinical outcome assessment (eCOA) solutions to replace costly and error-prone paper assessments with real-time data capture. The company’s clinical trials solutions include quality assurance services for study endpoints that combine innovative operational approaches, advanced analytics and scientific consulting. For over 20 years, Cogstate has proudly supported the leading-edge research needs of biopharmaceutical companies and academic institutions, and the clinical care needs of physicians and patients around the world. In the Healthcare market, Cogstate seeks to provide primary care physicians and consumers with brief, accurate and scientifically validated digital measures of cognition, with a focus on easy to use, self-administered tests that inform patients and save physician time. For more information, please visit www.cogstate.com. For further information contact: Brad O’Connor, Chief Executive Officer, boconnor@cogstate.com